Literature DB >> 11925089

Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.

James C Wittig1, Jacob Bickels, Dennis Priebat, James Jelinek, Kristen Kellar-Graney, Barr Shmookler, Martin M Malawer.   

Abstract

The treatment of osteosarcoma requires a multidisciplinary approach involving the family physician, orthopedic oncologist, medical oncologist, radiologist and pathologist. Osteosarcoma is a mesenchymally derived, high-grade bone sarcoma. It is the third most common malignancy in children and adolescents. The most frequent sites of origin are the distal femur, proximal tibia and proximal humerus. Patients typically present with pain, swelling, localized enlargement of the extremity and, occasionally, pathologic fracture. Most patients present with localized disease. Radiographs commonly demonstrate a mixed sclerotic and lytic lesion arising in the metaphyseal region of the involved bone. Computed tomography and bone scanning are recommended to detect pulmonary and bone metastases, respectively. Before 1970, osteosarcomas were treated with amputation. Survival was poor: 80 percent of patients died from metastatic disease. With the development of induction and adjuvant chemotherapy protocols, advances in surgical techniques and improvements in radiologic staging studies, 90 to 95 percent of patients with osteosarcoma can now be treated with limb-sparing resection and reconstruction. Long-term survival and cure rates have increased to between 60 and 80 percent in patients with localized disease.

Entities:  

Mesh:

Year:  2002        PMID: 11925089

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  91 in total

1.  The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma.

Authors:  Xuhui Zhou; Bo Yuan; Wen Yuan; Ce Wang; Rui Gao; Junyan Wang
Journal:  Tumour Biol       Date:  2014-04-02

2.  Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study.

Authors:  Huading Lu; Lei Zhu; Liyi Lian; Mingwei Chen; Dehai Shi; Kun Wang
Journal:  Tumour Biol       Date:  2015-02-09

3.  miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy.

Authors:  Shibing Guo; Rui Bai; Wanlin Liu; Aiqing Zhao; Zhenqun Zhao; Yuxin Wang; Yong Wang; Wei Zhao; Wenxuan Wang
Journal:  Tumour Biol       Date:  2014-04-22

4.  Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.

Authors:  Crispin R Dass; Anne P W Nadesapillai; Daniel Robin; Monique L Howard; Jane L Fisher; Hong Zhou; Peter F M Choong
Journal:  Clin Exp Metastasis       Date:  2006-04-29       Impact factor: 5.150

5.  Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population.

Authors:  Li-Qiang Zhi; Wei Ma; Hong Zhang; Si-Xiang Zeng; Bo Chen
Journal:  Tumour Biol       Date:  2013-11-28

6.  Differential enhancement of collagen crosslink excretion in cases of osteosarcoma and chondrosarcoma.

Authors:  Yahya Açil; Ingo Springer; Peter Behrens; Klaus-Peter Ullrich; Juergen Hedderich; Juergen Bruns
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-28       Impact factor: 4.553

7.  Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression.

Authors:  Rui Wang; Ke Dong; Fang Lin; Xi Wang; Ping Gao; San-Hua Wei; Shi-Yin Cheng; Hui-Zhong Zhang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

8.  Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.

Authors:  Yuanxun Yang; Yan Jin; Wenxi Du
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.

Authors:  Shizhang Liu; Zhi Yi; Ming Ling; Jiyuan Shi; Yusheng Qiu; Shujuan Yang
Journal:  Tumour Biol       Date:  2014-07-05

10.  Overexpression of long non-coding RNA HOTTIP increases chemoresistance of osteosarcoma cell by activating the Wnt/β-catenin pathway.

Authors:  Zhenwei Li; Liang Zhao; Qiugen Wang
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.